The new vaccine committee appointed by Secretary Robert F. Kennedy Jr. took minimal action in its first meeting.

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

Session ID: 2025-07-03:9a61974b939236f32b419e45 Player Element ID: V3f69f3ef_05ce_43e7_acbe_c951afabbbb5_6374131301112 ...

RSV hospitalizations were also down by about 19%. During the 2024-25 season, there were 1,269 hospitalizations due to RSV, as of the week ending in June 7, compared to 1,567 in 2023-24.